13 citations
,
June 2023 in “Frontiers in Pharmacology” Trastuzumab deruxtecan is effective for advanced breast cancer but has side effects like nausea and fatigue.
1 citations
,
July 2021 in “Frontiers in Oncology” Neoadjuvant endocrine therapy led to a better future outlook than chemotherapy, with no major quality of life differences.
January 2026 in “International Journal of Endocrinology” Lowering HER2 levels with certain drugs may reduce metabolic syndrome risk in women.
June 2026 in “Journal of cancer research updates” Generic Palbociclib is safe and tolerable for treating certain breast cancer types.
June 2024 in “Journal of Clinical Oncology” Dalpiciclib is the safest and most satisfying CDK4/6 inhibitor for advanced breast cancer patients in China.